[Comment] Ipilimumab with fotemustine in metastatic melanoma
01:30 EDT 13 Aug 2012 | The Lancet
Ipilimumab—an antibody against cytotoxic T-lymphocyte-associated protein 4—was the first systemic treatment in unresectable metastatic melanoma to be proven to extend overall survival. No previous phase 3 trial had shown any significant survival..
Original Article: [Comment] Ipilimumab with fotemustine in metastatic melanoma
More From BioPortfolio on "[Comment] Ipilimumab with fotemustine in metastatic melanoma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
